49 completed. 49 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 49 | Completed 49 |
| Phase 2 | 2 | Completed 2 |
Follow Vancomycin: new trials by email Literature Review of Vancomycin trials Research Report on Vancomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Intrawound Vancomycin in Spine Surgery vancomycin, Standard surgical closure - Surgical Site Infection (SSI), Spine Diseases | Phase 3 | Completed | Ain Shams University | 416 | 2023-12-02 | 2026-10-15 |
| Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection Oral Vancomycin, Placebo - Clostridioides Difficile Infection | Phase 3 | Completed | Julia Orígüen | 24 | 2022-08-02 | 2024-12-12 |
| Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection Vancomycin, Placebos - Clostridium Difficile Infection | Phase 3 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 263 | 2020-11-19 | 2025-12-10 |
| Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Ridinilazole, Vancomycin - Clostridioides Difficile Infection | Phase 3 | Completed | Summit Therapeutics | 759 | 2019-01-28 | 2026-10-09 |
| Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement Vancomycin - Arthropathy of Knee Joint | Phase 2 / Phase 3 | Completed | Mayo Clinic | 24 | 2018-09-24 | 2020-01-27 |
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Dalbavancin, Vancomycin, Oxacillin - Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Completed | AbbVie | 199 | 2017-03-30 | 2024-09-19 |
| Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection Fecal microbiota transplantation, Fidaxomicin, Vancomycin - Clostridium Difficile Infection | Phase 3 | Completed | University of Aarhus | 64 | 2016-04-01 | 2019-10-15 |
| Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus Amoxicillin, Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin - Infective Endocarditis | Phase 3 | Completed | University Hospital, Tours | 324 | 2016-02-29 | 2026-02-12 |
| Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2 Iclaprim, Vancomycin - Skin Structures and Soft Tissue Infections | Phase 3 | Completed | Motif Bio | 613 | 2015-11-01 | 2018-08-07 |
| Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 iclaprim, vancomycin - Skin Structures and Soft Tissue Infections | Phase 3 | Completed | Motif Bio | 600 | 2015-11-01 | 2018-06-19 |
| Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) Tedizolid Phophate, Antibiotic comparator, Aztreonam - Skin Diseases, Infectious, Skin Diseases, Bacterial | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 120 | 2015-03-25 | 2019-08-07 |
| A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid - Clostridium Difficile-associated Diarrhea (CDAD) | Phase 3 | Completed | Astellas Pharma Europe B.V. | 148 | 2015-01-09 | 2024-11-26 |
| Topical Vancomycin for Neurosurgery Wound Prophylaxis Vancomycin - Infection, Surgery | Phase 3 | Completed | Columbia University | 1103 | 2014-10-01 | 2025-10-29 |
| A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD) OPT-80, vancomycin - Clostridium Difficile | Phase 3 | Completed | Astellas Pharma Inc | 210 | 2014-06-23 | 2024-10-31 |
| Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections delafloxacin, vancomycin, aztreonam - Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections | Phase 3 | Completed | Melinta Therapeutics, Inc. | 850 | 2014-05-01 | 2017-11-17 |
| Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea Cadazolid, Vancomycin, Cadazolid-matching placebo - Clostridium Difficile Infection | Phase 3 | Completed | Actelion | 632 | 2014-03-27 | 2025-02-04 |
| Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea Cadazolid, Vancomycin, Cadazolid-matching placebo - Clostridium Difficile Infection | Phase 3 | Completed | Actelion | 631 | 2013-12-12 | 2025-02-04 |
| Regional Prophylactic Vancomycin in Revision Total Knee Replacement Vancomycin - Arthropathy of Knee Joint | Phase 2 / Phase 3 | Completed | Mayo Clinic | 22 | 2013-12-01 | 2016-11-25 |
| Staphylococcus Aureus Bacteremia Antibiotic Treatment Options Trimethoprim-Sulfamethoxazole, Clindamycin, Linezolid - Staphylococcus Aureus Infection | Phase 3 | Completed | Heinrich-Heine University, Duesseldorf | 215 | 2013-12-01 | 2020-05-27 |
| Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006) Daptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent) - Acute Hematogenous Osteomyelitis | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 149 | 2013-09-13 | 2018-08-28 |
Showing 20 of 49. Sign in to see all of them.
Clostridium Infections (12) · Cellulitis (11) · Bacterial Infections (8) · Skin Diseases, Bacterial (7) · Staphylococcal Skin Infections (7) · Abscess (6) · Infections (6) · Staphylococcal Infections (6) · Surgical Wound Infection (6) · Diarrhea (5) · Soft Tissue Infections (5) · Wound Infection (5) · Skin Diseases, Infectious (4) · Pneumonia, Bacterial (2) · Sepsis (2)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4) · Cumberland Pharmaceuticals (4) · Melinta Therapeutics, Inc. (4) · Pfizer (3) · Actelion (2) · Basilea Pharmaceutica (2) · Durata Therapeutics Inc., an affiliate of Allergan plc (2) · Forest Laboratories (2) · Mayo Clinic (2) · Motif Bio (2) · Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · AbbVie (1) · Ain Shams University (1) · Astellas Pharma Europe B.V. (1) · Astellas Pharma Inc (1)
United States (26) · Germany (10) · Argentina (9) · Russia (9) · Spain (9) · Poland (8) · Romania (8) · Ukraine (8) · Brazil (7) · Chile (7) · Bulgaria (6) · Canada (6) · France (6) · Israel (6) · Latvia (6)
G. Ralph Corey, MD (6) · Anne Claire Marrast, MD (2) · Michael Dunne, MD (2) · Achim J Kaasch, MD (1) · Christian Ramers, MD (1) · David Huang, MD, PhD (1) · David Melnick, MSD (1) · Dr. Sherwood Gorbach, MD (1) · E. Sander Connolly, M.D. (1) · Emily G McDonald, MD MSc (1)
PMID 30597021, PMID 30716446, PMID 34741280, PMID 34922058, PMID 18444791, PMID 19095213, PMID 20695801, PMID 21115456, PMID 22416054, PMID 22752857, PMID 22752865, PMID 23715579, PMID 24599770, PMID 24708675, PMID 24897082, PMID 27370913, PMID 27718118, PMID 28630189, PMID 29358292, PMID 29454592, PMID 29680101, PMID 29783024, PMID 30349845, PMID 30709665, PMID 32747931, PMID 34905144, PMID 18225981, PMID 19036671, PMID 21115454, PMID 21115455, PMID 21288078, PMID 22321770, PMID 22752860, PMID 22752862, PMID 23054338, PMID 24897083, PMID 25294250, PMID 25977146, PMID 26452342, PMID 27182626, PMID 27585969, PMID 28480267, PMID 28961905, PMID 29029278, PMID 29281036, PMID 29518178, PMID 29530858, PMID 29934056, PMID 30380060, PMID 30554184
2014 (2), 2009 (1)